TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33407609
Drug: Sterol-enriched yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterol-enriched yogurt (1.6 g/die)
Study: 32159711
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus immediate access to Deprexis
Study: 32159711
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus delayed access to Deprexis (after 8 weeks)
Study: 34471452
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (boxing/martial arts)
Study: 32356115
Drug: Abatacept 125
Normalized name: abatacept 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 125 mg weekly for 24 weeks
Study: 36128636
Drug: Continuous entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous entecavir monotherapy
Study: 33278364
Drug: Perturbation-based pinch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perturbation-based pinch task training (20 minutes per session, twice a week for 6 weeks)
Study: 33278364
Drug: Task-specific motor
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-specific motor training (20 minutes per session, twice a week for 6 weeks)
Study: 39222896
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical therapy alone)
Study: 35704394
Drug: OnabotulinumtoxinA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (all higher doses)
Study: 35271478
Drug: Enteral lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral lactoferrin supplementation (100 mg/day until PMA of 36 weeks or discharge)
Study: 33155461
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen and IM pethidine (Group A)
Study: 33155461
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen and IV parecoxib (Group B)
Study: 33155461
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen monotherapy (Group C)
Study: 35653761
Drug: Daily skin-to-skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily skin-to-skin contact (SSC) for 1 hour daily for the first 5 weeks postpartum
Study: 35653761
Drug: Daily skin-to-skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily skin-to-skin contact (SSC)
Study: 34385241
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg/day plus LHRHa
Study: 35371278
Drug: ESWT combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWT combined with wIRA therapy
Study: 35371278
Drug: wIRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: wIRA therapy (Control)
Study: 32609979
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 3 days
Study: 35934873
Drug: Emergency umbilical
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency umbilical button cannula (EUC) using lateral umbilical cord incision (L-EUC)
Study: 32917473
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) with low-energy flux density (0.05–0.30 mJ/mm2)
Study: 32605536
Drug: Daily questioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily questioning
Study: 33545548
Drug: Bufei Yishen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufei Yishen formula (BYF) combined with conventional Western medicine
Study: 33545548
Drug: Key active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Key active molecules (KAM) of BYF
Study: 33966913
Drug: Buccal chamfer
Normalized name: HOLDING CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal chamfer
Study: 32888370
Drug: Secukinumab (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (standard dose)
Study: 36040362
Drug: 99.9% pure
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99.9% pure CBD (200 mg/day for 2 weeks, then 300 mg/day for 10 weeks)
Study: 33441010
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with 1 × 10^6/ml spore suspension of Fusarium redolens
Study: 35164986
Drug: FINLAY-FR-1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FINLAY-FR-1 (50 µg d-RBD plus outer membrane vesicles from N. meningitidis)
Study: 35164986
Drug: FINLAY-FR-1A-50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FINLAY-FR-1A-50 (50 µg d-RBD, three doses)
Study: 35164986
Drug: FINLAY-FR-1A-25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FINLAY-FR-1A-25 (25 µg d-RDB, three doses)
Study: 32538747
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid parenteral nutrition
Study: 32538747
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (equal-nitrogen and equal-calorie enteral and parenteral nutrition)
Study: 33348306
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 20 minutes, done for three consecutive days.
Study: 35421086
Drug: Morning bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning bright light therapy (10,000 lux at the eye) for 60 minutes every morning for 4 weeks
Study: 35421086
Drug: Morning bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning bright light therapy
Study: 35183882
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of boron citrate twice a day
Study: 35183882
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of oleoylethanolamide twice a day
Study: 35183882
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (5 mg of boron citrate and 200 mg of oleoylethanolamide)
Study: 35183882
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments without any study medications (Control)
Study: 35781459
Drug: Anifrolumab (Saphnelo®)
Normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab (Saphnelo®) administered as an intravenous infusion, 300 mg over a 30-minute period, every 4 weeks
Study: 32377783
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g TXA (intravenous)
Study: 32377783
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g TXA (topical)
Study: 32377783
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g TXA (combined intravenous + topical)
Study: 32377783
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g TXA (combined + group)
Study: 34137514
Drug: Aomei meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aomei meloxicam (15 mg)
Study: 34137514
Drug: Mobic meloxicam
Normalized name: meloxicam Oral Tablet [Mobic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobic meloxicam (15 mg)
Study: 32700572
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of lipid lowering (treatment for 30 years) in 40- to 49-year-old patients with non-HDL-C ≥160 mg/dL
Study: 32700572
Drug: Delaying lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delaying lipid lowering by 10 years (treatment for 20 years)
Study: 32700572
Drug: Delaying lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delaying lipid lowering by 20 years (treatment for 10 years)
Study: 35704027
Drug: 3.2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g/day sunflower oil (placebo)
Study: 32859542
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus physical therapy
Study: 35440469
Drug: Colchicine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (500 µg daily for 14 days)
Study: 34285701
Drug: Berberis integerrima
Normalized name: BERBERIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberis integerrima fruit extract (1000 mg daily, 5 ml twice daily)
Study: 34285701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with metformin only)
Study: 35394723
Drug: Alental cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alental cream
Study: 35394723
Drug: Aertal cream
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aertal cream
Study: 34458708
Drug: Pooled RT-qPCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled RT-qPCR testing using oropharyngeal swabs or buccal swabs
Study: 35501931
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) treatment initiated one day post-injury
Study: 35501931
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) treatment
Study: 35272249
Drug: Dry-needling together
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry-needling together with exercise therapy (DNG)
Study: 33222767
Drug: MD1003 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD1003 (oral biotin 100 mg three times daily)
Study: 33161105
Drug: Probucol combined
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol combined with mecobalamin tablets
Study: 33161105
Drug: Control (mecobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (mecobalamin tablets only)
Study: 35484429
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at 10 IU/h
Study: 35484429
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at 5 IU/h
Study: 35484429
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at 2.5 IU/h
Study: 34616527
Drug: Conventional acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acute angina pectoris drugs
Study: 33863746
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment (n=17)
Study: 34588252
Drug: Mirabegron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (50 mg orally once a day)
Study: 35393934
Drug: Brief behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief behavioral treatment for insomnia (BBTI, 4 sessions)
Study: 35393934
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation therapy (active control)
Study: 35360485
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine hot ironing technique intervention
Study: 37244291
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin supplement (Centrum Silver)
Study: 34556107
Drug: Chitosan-based varnish
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan-based varnish (UNO Gel Bioschell, Germiphene corp.) applied weekly for 6 weeks
Study: 34556107
Drug: Chlorhexidine-fluoride varnish
Normalized name: chlorhexidine / sodium fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-fluoride varnish (Cervitec F, Ivoclar Vivadent) applied weekly for 6 weeks
Study: 32215834
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg daily for 1 week
Study: 36089229
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP, 4 intra-articular saline injections over 8 weeks)
Study: 34532299
Drug: Rifaximin, 550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin, 550 mg twice daily
Study: 34790373
Drug: Carbon nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticles suspension injections (CNS) administered endoscopically within 24 hours prior to neoadjuvant chemotherapy (NCT).
Study: 35732064
Drug: Higher Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Brain Living (HBL) therapy
Study: 36066854
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d of trans-resveratrol (RSV) for 3 months (90 days)
Study: 36066854
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d of trans-resveratrol (RSV)
Study: 616631076
Drug: lienal polypeptide
Normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lienal polypeptide injection combined with chemotherapy
Study: 616631076
Drug: chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy only
Study: 35695582
Drug: Mirtazapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (mean dosage = 39.56 mg/day)
Study: 33601937
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) [Octagam 5%]
Study: 32398120
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment algorithm based on ultrasonographic examination
Study: 32398120
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (Control group A)
Study: 32398120
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (Control group B)
Study: 33165168
Drug: PGx‐treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGx‐treatment group (200 mg isoniazid)
Study: 33165168
Drug: Standard‐treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐treatment group (300 mg isoniazid)
Study: 33165168
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (300 mg isoniazid for NAT2 rapid acetylators)
Study: 35314092
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment (specific dosage and duration not mentioned)
Study: 36266402
Drug: 1-week residential
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week residential group program based on mindfulness training, artistic expression, and EMDR group therapy
Study: 33099934
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg/3 weeks
Study: 33099934
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg/3 weeks with primary surgery
Study: 33099934
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg/3 weeks with secondary debulking surgery
Study: 33008855
Drug: 2-event regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-event regimen (2 pills per day)
Study: 33008855
Drug: 3-event regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-event regimen (3 pills per day)
Study: 33008855
Drug: 4-event regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-event regimen (4 pills per day)
Study: 33008855
Drug: Chewable calcium
Normalized name: Chewable Calcium
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable calcium supplements
Study: 32111803
Drug: MRI after
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI after neoadjuvant chemotherapy
Study: 34903704
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 500 mg metronidazole and 3 × 1.5 g cefuroxime intravenously for 3 days starting on the day before RC
Study: 33752119
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% plus clonidine (2 mcg/kg, maximum of 100 mcg)
Study: 37702442
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated group)
Study: 34973284
Drug: PTC923 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 60 mg/kg
Study: 34973284
Drug: PTC923 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 20 mg/kg
Study: 34973284
Drug: Sapropterin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin 20 mg/kg
Study: 34973284
Drug: PTC923 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 60 mg/kg vs. Sapropterin
Study: 34973284
Drug: PTC923 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 20 mg/kg vs. Sapropterin
Study: 34973284
Drug: PTC923 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 60 mg/kg in classical PKU subjects
Study: 34973284
Drug: PTC923 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 60 mg/kg cofactor responder analysis
Study: 33290857
Drug: Parenteral oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral oxycodone
Study: 33290857
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between oxycodone and morphine
Study: 33485369
Drug: rVSV?G‐ZEBOV‐GP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV?G‐ZEBOV‐GP vaccine (with and without booster dose at 56 days)
Study: 33485369
Drug: Ad26.ZEBOV,MVA‐FN‐Filo vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV,MVA‐FN‐Filo vaccine regimen (Ad26.ZEBOV first dose, MVA‐FN‐Filo 56 days later)
Study: 34999321
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron intake below average requirement of 5 mg/day in infants
Study: 34999321
Drug: Higher daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher daily iron intake per body weight (mg/kg)
Study: 32489080
Drug: Kuntai Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai Capsules combined with GnRH-a
Study: 35748777
Drug: ZOL 30
Normalized name: Zol
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ZOL 30 mg
Study: 35748777
Drug: SUV 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUV 40 mg
Study: 32079487
Drug: Radioiodine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine treatment (131I)
Study: 33298062
Drug: BDP/F/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/F/G
Study: 33819214
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous ultrasound (3 sessions per week for 7 weeks)
Study: 33819214
Drug: Far-infrared treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far-infrared treatment (3 sessions per week for 7 weeks)
Study: 36172719
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative medicine (OMM) - 2 treatments
Study: 36172719
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative medicine (OMM) - 1 treatment
Study: 32710204
Drug: Hyperthermic IPEC
Normalized name: Ipecac
DrugBank: Ipecac (DB13293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic IPEC of cisplatin (75, 100, and 120 mg/m2)
Study: 32710204
Drug: Normothermic IPEC
Normalized name: Ipecac
DrugBank: Ipecac (DB13293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic IPEC of cisplatin (75, 100, and 120 mg/m2)
Study: 32710204
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) with IPEC duration of 1-2 hours
Study: 32710204
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 and 120 mg/m2) with IPEC duration of 1 hour
Study: 32710204
Drug: Cisplatin (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75, 100, and 120 mg/m2)
Study: 34518254
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg for a minimum of 12 weeks before surgery
Study: 33751727
Drug: Medications (bronchodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications (bronchodilators and inhaled corticosteroids)
Study: 33751727
Drug: Preventive strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive strategies and treatments that alter the course of disease
Study: 34808726
Drug: onaBotulinum Toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: onaBotulinum Toxin type A injection (100 units)
Study: 35965162
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen (1,000 mg)
Study: 35965162
Drug: Intravenous Hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Hydromorphone (0.5 mg)
Study: 33044990
Drug: Empathetic approach
Normalized name: Bos taurus sympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empathetic approach in treatment and long-term follow-up
Study: 32589775
Drug: Remdesivir (RDV)
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir (RDV) 75 mg or 150 mg lyophilized formulation infused over 30 minutes or 2 hours
Study: 32589775
Drug: Remdesivir (RDV)
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir (RDV) 150 mg once daily for 7 or 14 days